Virpax Pharmaceuticals (VRPX) 10-Q2024 Q1 Quarterly report

Filed: 13 May 24, 4:02pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: arising, avoidance, battlefield, binding, bridging, burn, captioned, cavity, CB, civil, COA, competitive, criminal, deactivation, declining, delinquency, Destum, difficulty, discharge, Dismissal, dismissing, District, dog, DS, earlier, easy, endocannabinoid, EnveltaTM, enzymatic, epithelial, EpoladermTM, evidence, excitability, fast, fifteen, filling, Fiorvanti, gas, gastrointestinal, GMP, Gudin, handling, imposition, indemnifiable, indemnification, indemnify, inert, intervention, Jeffrey, Jerusalem, judicial, letter, LGS, liver, lower, manner, MD, metabolism, motion, negotiating, neuronal, noncompliance, Notwithstanding, Orphan, pathophysiology, PCT, pediatric, pending, peripheral, Plaintiff, pressurized, ProbudurTM, reasserting, reclassified, reclassifying, registered, resolve, resolved, resurgence, retroactively, sealed, side, solution, sought, Southern, Stipulation, subdivided, suit, theory, threatened, tract, underlying, unsuccessful, upper, validly, vivo

Removed: appeal, appointed, argument, array, assessment, augment, automatically, CMC, consecutive, countered, defend, delayed, Department, dilutive, execution, expanding, expansion, extend, fifteenth, finalizing, Fioravanti, firm, imply, inclusive, inherently, initiated, involved, lifetime, newly, NobrXiolTM, operative, opportunistically, panel, portrayal, present, reach, reflect, River, serving, slightly, strategically, structured, unsupported, vested, wide

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

VRPX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Vinay Shah, Chief Financial Officer (Principal Financial and Accounting Officer) of Virpax Pharmaceuticals, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)

The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Form 10-Q”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented.

Date: May 13, 2024

	By:	/s/ Vinay Shah
		Vinay Shah
		Chief Financial Officer
		(Principal Financial and Accounting Officer)